All News
CAR-T Cell Therapies Show Promise for Autoimmune Disease at ACR Convergence 2025
Two pioneering studies presented at ACR Convergence 2025 spotlight the potential of CAR-T cell therapies to transform treatment for systemic lupus erythematosus (SLE) and other autoimmune diseases.
Read Article
Sooner May Still Be Too Late: Kidney Biopsies in SLE
ACR Convergence 2025 will be kicking off with a Plenary Session by Michelle Petri (Abstract 0772: Redefining When to Biopsy the Kidney in Patients with SLE), which is a great place to kick off our coverage of the meeting. As part of a collaboration with the Accelerating Medicines Partnership, Petri and colleagues have given data to what many of us have long suspected: a biopsy threshold of 0.5g/d of proteinuria may be too high.
Read Article
Pre-ACR25 (10.24.2025)
Dr. Jack Cush reviews the news and info reports the day before ACR 2025
Read Article
Can Steroids Be Stopped in Lupus Nephritis?
Patients with lupus nephritis were more likely to get off chronic corticosteroid treatment, and stay off, when certain factors were in place, researchers said.
Read Article
Clinical and Genetic Effects of Neuropsychiatric Lupus
The clinical features and genetic abnormalities of neuropsychiatric systemic lupus erythematosus shows that NPSLE often means more severe lupus and more organ involvement beyond the central nervous system.
Read Article
SGLT-2 inhibitors and the prevention of autoimmune rheumatic disease
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors have benefits beyond glycemic control, including cardioprotective and nephroprotective effects, with modest weight loss.
Read Article
FDA Approves Obinutuzumab for Active Lupus Nephritis
The FDA has approved obinutuzumab (Gazyva) for the treatment of lupus nephritis. This is good news for the more than 1.7 million people worldwide with lupus nephritis.
Read Article
Bad Actor Cofactor (10.17.2025)
Dr. Jack Cush reviews the news and journal reports, discusses pediatric reports, pregnancy data, diet and nutrition and more.
Read Article
Telitacicept Effective in Systemic Lupus Erythematosus
The NEJM has published a report from van Vollenhoven et al showing a new dual B cell inhibitor, telitacicept, to be effective when given to active systemic lupus erythematosus (SLE) patients; but this comes with a few safety concerns.
Dr. John Cush RheumNow ( View Tweet)
Links:
Osteonecrosis: suspect with trauma, high-dose steroids, alcoholism, renal failure, transplantation, SLE, thrombotic states (e.g., sickle cell anemia, hemoglobinopathies), radiation injury, pancreatitis, gout, pregnancy, hyperlipidemia, & caisson disease (decompression sickness) https://t.co/y6iYd5fWZ2
